EVALUATION OF 7 TUMOR-MARKERS (CA 50, CA 19-9, CA 19-9 TRUQUANT, CA 72-4, CA 195, CARCINOEMBRYONIC ANTIGEN, AND TISSUE POLYPEPTIDE ANTIGEN)IN THE PRETREATMENT SERA OF PATIENTS WITH GASTRIC-CARCINOMA

Citation
T. Wobbes et al., EVALUATION OF 7 TUMOR-MARKERS (CA 50, CA 19-9, CA 19-9 TRUQUANT, CA 72-4, CA 195, CARCINOEMBRYONIC ANTIGEN, AND TISSUE POLYPEPTIDE ANTIGEN)IN THE PRETREATMENT SERA OF PATIENTS WITH GASTRIC-CARCINOMA, Cancer, 69(8), 1992, pp. 2036-2041
Citations number
9
Language
INGLESE
art.tipo
Article
Journal title
CancerACNP
ISSN journal
0008-543X
Volume
69
Issue
8
Year of publication
1992
Pages
2036 - 2041
Database
ISI
SICI code
0008-543X(1992)69:8<2036:EO7T(5>2.0.ZU;2-U
Abstract
Preoperative serum levels of the tumor markers CA 50, CA 19-9, CA 19-9 TruQuant, CA 72-4, CA 195, carcinoembryonic antigen (CEA), and tissue polypeptide antigen (TPA) were measured in 94 patients with well-stag ed adenocarcinoma of the stomach and in 15 patients with benign gastri c diseases. In all patients with carcinoma, a laparotomy was done. The serum levels were correlated with the stage of disease, the location of the primary tumor, and the resectability and grade of differentiati on. The marker CA 50 was the best, with an overall positivity of 59.5% . For CA 19-9, this figure was 34%; for CA 19-9 TruQuant, 22%; for CA 72-4, 34%; for CA 195, 29%; for CEA, 33%; and for TPA, 50%. The best c ombination of two markers was CA 50 and TPA; this combination gave a p ositivity of 81%. There was no evident correlation with stage of disea se and the percentage of positive serum levels or the median serum lev els. The marker CA 50 gave the widest range of elevated serum levels b etween the cutoff level and the 90th percentile (54%). Patients with c arcinoma of the cardia had higher preoperative serum levels than those with a tumor in other parts of the stomach. There was no correlation with the resectability of the tumor and the preoperative serum level. Patients with an undifferentiated tumors did not have significantly lo wer serum levels than those with more differentiated tumors. Currently , preoperative determination of serum tumor marker levels in patients with gastric carcinoma has no significance in clinical practice.